Biotec,

here the future has arrived

  • Biological drugs represent the most modern resources in the treatment of various pathologies, among them cancer and autoimmune diseases. And we are already producing these drugs in Brazil, making them available to more people, reducing the technological dependence and vulnerability of our country against the international market.

    Biotec allowed us to meet the most demanding requirements of national and international regulatory bodies – making our plant a platform for development, production and export of biomedicine drugs.

  • Our distinctions

    With a total production capacity of 400 kg of biopharmaceutical products per year, our Biotec applies the single-use system, a technology based on bioreactors with disposable bags. The main advantages of this system are flexibility and process optimization, as disposable bags do not require decontamination and cleaning operations.

  • What does this mean for Brazil?

    The consolidation of Biotec is a great achievement, not only for us, but for the country as a whole. “This is an enterprise that requires high technical capacity and skilled labor – and Libbs meets these requirements. We expect that this partnership, besides expanding the access to biological medicines in Brazil, also promotes competitiveness in this market”, emphasizes the ex-Minister of Health, Ricardo Barros. Moreover, the national production of biosimilar medicines also contributes to reduce our dependence on imports of these products, which currently represent a high cost for the Ministry of Health.

  • Our portfolio

    Among our biosimilars we can list
    – trastuzumab: treatment of metastatic breast cancer, early breast cancer and advanced gastric cancer.
    – rituximab: for treatment of non-Hodgkin lymphoma, follicular lymphoma, rheumatoid arthritis, chronic lymphoid leukemia and other autoimmune diseases.
    – bevacizumab: treatment of metastatic colorectal cancer, locally advanced, metastatic or recurrent non-small cell lung cancer, metastatic or locally recurrent breast cancer, metastatic and/or advanced renal cell cancer.
    – etanercept: treatment of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis and chronic psoriasis.
    – adalimumab: treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, plaque psoriasis and polyarticular juvenile psoriatic arthritis.

  • A bit of history

    Biotec began to be built in 2013, however, the walk needed to make this project real began much earlier. “Initially, it was difficult to convince researchers of the feasibility of producing biological drugs in Brazil. However, the biggest challenge was to make so many things happen in a short time”, recalls our president, Alcebíades Junior.

    In order to carry out such a complex project, we employed parallel fronts, ranging from civil works to technological partnerships, as well as national and international clinical studies. For that, we relied on the support of mAbxience, a Spanish pharmaceutical company of the Chemo group, which helped us in the transfer of the biosimilar production technology.

  • Learn more

    Biosimilars are a reality worldwide and now they are even more present in our country. To learn more, please visit us on Biossimilares Brasil. In this portal you will discover the advantages of these treatments and will have access to studies and the latest news on biosimilars. The website also offers information related to the greater access brought by these drugs, types approved in Brazil & abroad, test methodologies and much more.